Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Recurrence 1Papillomavirus Infections 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Gliosarcoma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Trastuzumab 25Paclitaxel 22Cyclophosphamide 20Docetaxel 17Taxes 14Lapatinib 13Doxorubicin 13Radiotherapy 12Bevacizumab 11Capecitabine 10Tamoxifen 9Immunohistochemistry 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Filgrastim 8Carboplatin 8Vorinostat 6Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6Chemotherapy, Adjuvant 6Biopsy 6Peripheral Blood Stem Cell Transplantation 5Everolimus 5liposomal doxorubicin 4ixabepilone 4Vinorelbine 4Neoadjuvant Therapy 4Immunoenzyme Techniques 4Gene Expression Profiling 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms, Male × Receptor Protein-Tyrosine Kinases × Clear all
NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Cancer Insight, LLC

Phase 2 Completed
275 enrolled 23 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡